lncRNA LUCAT1 regulates DNA damage response in glioma stem cells under hypoxia
Neuro-Oncology · 2026
DOI: 10.1093/neuonc/noag017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Haidong Huang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Sciences, Cleveland Clinic, Cleveland, OH, United States. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, RNA, Long Noncoding, DNA Damage, Glioma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institutes of Health, VeloSano to J.S.Y., Cleveland Clinic to J.S.Y., Case Comprehensive Cancer Center to J.S.Y., Amy Post Fund to J.S.Y., and Falk Foundation Medical Research Trust….
Abstract (Originalsprache)
Background
Genomic stability is essential for cell survival, particularly under stress conditions like hypoxia, which disrupt DNA repair. Glioblastoma (GBM) is markedly resistant to DNA-damaging therapies, primarily due to glioma stem cells (GSCs) and the hypoxic tumor microenvironment. Long non-coding RNAs (lncRNAs) play a significant role in maintaining genome integrity, but their involvement in the DNA damage response (DDR) under hypoxic conditions in GSCs remains unclear. We previously identified LUCAT1 as the most highly induced lncRNA in GSCs under hypoxia and a key regulator HIF1α activity. We now investigate its role in DDR regulation.
Methods
LUCAT1-interacting proteins in GSCs under hypoxia were identified using identification of direct RNA interacting proteins (iDRIP) and mass spectrometry. Interactions were confirmed by RNA pulldown and RNA immunoprecipitation. Mechanistic studies involved immunoprecipitation, proximity ligation assays, comet assays, immunostaining, and LUCAT1 knockdown using shRNA. Gene expression changes were evaluated via RNAseq in GSCs and TCGA datasets. Functional assays were conducted in GSCs and orthotopic xenografts with LUCAT1 depletion alone or in combination with PARP or DNA-PK inhibition or radiation.
Results
LUCAT1 directly interacts with the DNA-PK holoenzyme, modulating its assembly and function in the non-homologous end joining (NHEJ) pathway. It also regulates BRCA1 and RAD51, key proteins in homologous recombination (HR). Depletion of LUCAT1 increased DNA damage, sensitized GSCs to DDR inhibitors, and improved survival in mice treated with radiotherapy.
Conclusions
LUCAT1 is a critical DDR regulator in GSCs under hypoxia and a promising target to enhance the efficacy of DDR inhibitors and radiotherapy in GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Sciences, Cleveland Clinic, Cleveland, OH, United States.
- Department of Pathology, Cleveland Clinic, Cleveland, OH, United States.
- Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, United States.
ORCID-Profile: Jennifer S Yu
Förderung
- National Institutes of Health
- VeloSano to J.S.Y., Cleveland Clinic to J.S.Y., Case Comprehensive Cancer Center to J.S.Y., Amy Post Fund to J.S.Y., and Falk Foundation Medical Research Trust…
Zitieren
APA
Huang, H., Shah, H., Dashora, H., Guthrie, M., MacLowry, L., Huang, Z., Khalife, D., Lin, J., Bao, S., Prayson, R., Xie, L., Zhao, J., & Yu, J. S. (2026). lncRNA LUCAT1 regulates DNA damage response in glioma stem cells under hypoxia. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag017
Vancouver
Huang H, Shah H, Dashora H, Guthrie M, MacLowry L, Huang Z, et al. lncRNA LUCAT1 regulates DNA damage response in glioma stem cells under hypoxia. Neuro-Oncology. 2026. doi:10.1093/neuonc/noag017
BibTeX
@article{Huang2026,
author = {Huang, Haidong and Shah, Hariti and Dashora, Himanshu and Guthrie, Molly and MacLowry, Lilah and Huang, Zhi and Khalife, Dalya and Lin, Jianhong and Bao, Shideng and Prayson, Richard and Xie, Liangqi and Zhao, Jianjun and Yu, Jennifer S},
title = {lncRNA LUCAT1 regulates DNA damage response in glioma stem cells under hypoxia},
journal = {Neuro-Oncology},
year = {2026},
doi = {10.1093/neuonc/noag017}
}
EUVIMED